Among last week’s news, US biotech Celcuity leapt 180% on new Phase III data for its cancer drug candidate gedatolisib. US drugmaker Madrigal Pharmaceuticals entered into a licensing deal with China’s ...

Upcoming Pharma and Biotech Events and Conferences23 September 2025, 25 September 2025 Dubai, UAE, Dubai World Trade Centre A premier trade show for the global laboratory and analytical industry in ...

The US Food and Drug Administration (FDA) approved San Diego, USA-based LENZ Therapeutics’ VIZZ (aceclidine ophthalmic ...

After nearly 27 years as a division of Swiss giant Novartis, generics and biosimilars specialist Sandoz (SWX: SDZ) went its ...

England has agreed to commission the use of Hemlibra (emicizumab) as a prophylactic treatment for patients of all ages with ...

German healthcare and crop sciences giant Bayer (BAYN DE) saw its share close up 2.8% at 28.12 euros, after it provided an ...

US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...

Swiss pharma giant Roche announced positive five-year efficacy, safety and durability data from the Phase III Portal study, a ...

Bristol Myers Squibb (NYSE: BMY) and Chinese biotech partner Sichuan Biokin (SHE: 688506) have reported a key win in the clinic, as their experimental antibody-drug conjugate iza-bren (izalontamab ...

Japanese pharma major Astellas Pharma (TSE: 4503) delivered a strong performance in fiscal 2024, with revenue rising 19% to 1.91 trillion yen ($12.6 billion) and core profit climbing 33% to 295.7 ...

US Biotech Regeneron Pharmaceuticals today announced financial results for the second quarter of 2025 and provided a business ...

US biotech major Biogen (Nasdaq: BIIB) reported a 7% rise in its second quarter revenue Friday, with sales of $2.45 billion.